The programme will involve presentations from academics and pharmaceutical industry analysts on the UK development and manufacturing context, the scope of applications, the role of pharmacopoeia, effective use of LC in QC / bioanalysis / biopharmaceuticals and examples of the use of modern LC technology in development and manufacture. However, ahead of the meeting analytical scientists supporting pharmaceutical development and manufacture were invited to comment on the most important unmet analytical needs they are facing. Arising from this, for the main part of the afternoon session, speakers and in particular vendors will be set the task of demonstrating how the following identified challenges might be met:
These themes will take up a large part of the afternoon session and the close of the meeting a panel / audience discussion will be held to consider whether these challenges are being satisfactorily addressed.
Confirmed speakers to date include: Chris Riley (SavaraPharma / RileyandRabel Consulting, USA), Tony Edge (University of Liverpool), Irene Areri (GSK), Daniel Meston (Helmhotz Research Institute, Germany), Ed Bush (AstraZeneca) and John Lough (University of Sunderland).
- the sheer number and variety of molecular entities coming through development and manufacture
- the range and variety of formulations now being encountered
- the need for automation in sample preparation for development and manufacture
- taking greater utilisation of preparative LC in pharmaceutical development and manufacture
- training
These themes will take up a large part of the afternoon session and the close of the meeting a panel / audience discussion will be held to consider whether these challenges are being satisfactorily addressed.
Confirmed speakers to date include: Chris Riley (SavaraPharma / RileyandRabel Consulting, USA), Tony Edge (University of Liverpool), Irene Areri (GSK), Daniel Meston (Helmhotz Research Institute, Germany), Ed Bush (AstraZeneca) and John Lough (University of Sunderland).
